| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
5-Dihydrocortisone targets endogenous metabolic pathways as a metabolite of cortisone. It is produced by the action of 5β-reductase (AKR1D1) in the liver. As an endogenous metabolite, it does not have a specific pharmacological target in the traditional sense but is used as a research tool to study steroid metabolism and the function of 5β-reductase. It belongs to the metabolic enzyme/protease pathway.
|
|---|---|
| ln Vitro |
In vitro activity of 5-Dihydrocortisone is related to its role as an endogenous metabolite and research tool for studying steroid metabolism. It is used to investigate the function of 5β-reductase (AKR1D1) in the liver. As a metabolite of cortisone, it may be used in studies of corticosteroid metabolism and the regulation of steroid hormone signaling. Detailed in vitro activity data, including enzyme assays, are not extensively documented in the available literature.
|
| ln Vivo |
In vivo activity of 5-Dihydrocortisone is related to its role as a naturally occurring metabolite of cortisone. It is produced in the liver by 5β-reductase (AKR1D1). As an endogenous metabolite, it may have physiological roles in steroid hormone metabolism and signaling. It is used as a research tool to study steroid metabolism in vivo. Detailed in vivo data are not extensively documented in the available literature.
|
| Enzyme Assay |
The in vitro enzyme/receptor binding assay for 5-Dihydrocortisone typically involves measuring its production by 5β-reductase (AKR1D1) or its activity as a substrate or product in steroid metabolism studies. Enzyme assays using purified AKR1D1 incubated with cortisone and NADPH are performed to measure the conversion to 5-dihydrocortisone. Product formation is quantified by HPLC or mass spectrometry. Standard protocols include appropriate controls and reference standards.
|
| Cell Assay |
In vitro cell-based assays for 5-Dihydrocortisone are conducted using hepatocyte cell lines to study steroid metabolism. Cells are treated with cortisone or related steroids, and the production of 5-dihydrocortisone is measured by LC-MS/MS. The effect of the compound on steroid hormone signaling pathways may be assessed by measuring downstream gene expression. Standard protocols include appropriate controls and reference standards for metabolite identification.
|
| Animal Protocol |
In vivo animal studies for 5-Dihydrocortisone would typically be conducted to study steroid metabolism and the function of 5β-reductase. Animals would be administered cortisone or related compounds, and levels of 5-dihydrocortisone in plasma and tissues would be measured by LC-MS/MS. However, detailed in vivo protocols and efficacy data are not available from the search results. The compound is intended for research use only.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 5-Dihydrocortisone include a molecular weight of 362.46 and a molecular formula of C21H30O5. The compound appears as a white to off-white solid. Storage recommendations include 4°C, sealed storage away from moisture and light, with in solvent stability at -80°C for 6 months or -20°C for 1 month. Detailed pharmacokinetic parameters are not extensively documented.
|
| Toxicity/Toxicokinetics |
Toxicity information for 5-Dihydrocortisone is limited. As an endogenous metabolite and research-use compound, standard safety precautions for handling should be followed. The compound is designated for research use only and is not for human therapeutic applications. No detailed toxicity data are available from the search results.
|
| References | |
| Additional Infomation |
4,5-Dihydrocortisone is a 3-oxosteroid, formed by the reduction of the double bond between the 4 and 5 positions of cortisone to a single bond. It is a 3-oxosteroid, 11-oxosteroid, 20-oxosteroid, 17α-hydroxysteroid, 21-hydroxysteroid, primary α-hydroxy ketone, and tertiary α-hydroxy ketone. Functionally, it is related to cortisone.
5-Dihydrocortisone is a sterol metabolite of cortisone produced by 5β-reductase (AKR1D1) in the liver. It is a mixture of isomers and an endogenous metabolite. The compound has a molecular weight of 362.46 and formula C21H30O5. It belongs to the metabolic enzyme/protease pathway. It is intended for research use only. |
| Molecular Formula |
C21H30O5
|
|---|---|
| Molecular Weight |
362.46
|
| Exact Mass |
362.209
|
| CAS # |
28423-48-5
|
| PubChem CID |
17756741
|
| Appearance |
White to off-white solid powder
|
| LogP |
2.069
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
26
|
| Complexity |
671
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
O[C@]1([C@]2(C)[C@H]([C@H]3[C@H](C(=O)C2)[C@]2(C)C(CC(=O)CC2)CC3)CC1)C(=O)CO
|
| InChi Key |
YCLWEYIBFOLMEM-AGIMVQGUSA-N
|
| InChi Code |
InChI=1S/C21H30O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h12,14-15,18,22,26H,3-11H2,1-2H3/t12?,14-,15-,18+,19-,20-,21-/m0/s1
|
| Chemical Name |
(8S,9S,10S,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-1,2,4,5,6,7,8,9,12,14,15,16-dodecahydrocyclopenta[a]phenanthrene-3,11-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Typically soluble in DMSO (e.g. 10 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7589 mL | 13.7946 mL | 27.5893 mL | |
| 5 mM | 0.5518 mL | 2.7589 mL | 5.5179 mL | |
| 10 mM | 0.2759 mL | 1.3795 mL | 2.7589 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
